Selenium combo shows promise in kidney cancer fight
NCT ID NCT05363631
First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 16 times
Summary
This study tests whether adding a selenium supplement (SLM) to two standard cancer drugs (axitinib and pembrolizumab) is safe and effective for people with advanced clear cell kidney cancer. About 55 participants will receive the combination therapy. The goal is to see if the supplement helps shrink tumors or slow disease progression without causing too many side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.